Inhibition of topoisomerase II alpha: Novel function of wedelolactone

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F11%3A00440847" target="_blank" >RIV/68081707:_____/11:00440847 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.canlet.2011.01.002" target="_blank" >http://dx.doi.org/10.1016/j.canlet.2011.01.002</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.canlet.2011.01.002" target="_blank" >10.1016/j.canlet.2011.01.002</a>

Result language
angličtina
Original language name
Inhibition of topoisomerase II alpha: Novel function of wedelolactone
Original language description
The naturally occurring coumestan wedelolactone has been previously shown to reduce growth of various cancer cells. So far, the growth-suppressing effect of wedelolactone has been attributed to the inhibition of the NF kappa B transcription factor and/orandrogen receptors. We found that wedelolactone suppressed growth and induced apoptosis of androgen receptor-negative MDA-MB-231 breast cancer cells at concentrations that did not inhibit the NF kappa B activity. The cells responded to wedelolactone bythe S and G2/M phase cell cycle arrest and induction of the DNA damage signaling. Wedelolactone interacted with dsDNA and inhibited the activity of DNA topoisomerase II alpha. We conclude that wedelolactone can act as growth suppressor independently of NF kappa B and androgen receptors. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
BO - Biophysics
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)